- Recently, Globant and PharmaMar announced a collaboration to apply Globant Enterprise AI in accelerating cancer drug discovery, while Globant and Adyen formalized a global partnership making Globant a lead integration partner for Adyen’s payments platform.
- Together, these alliances show how Globant is embedding its AI and integration capabilities at the core of critical workflows in both healthcare R&D and global payments infrastructure.
- Now we’ll examine how Globant’s AI-powered PharmaMar platform for faster cancer drug discovery could influence its broader investment narrative.
Outshine the giants: these 21 early-stage AI stocks could fund your retirement.
Globant Investment Narrative Recap
To own Globant, you need to believe its Enterprise AI and industry studios can convert a strong pipeline into healthier growth despite muted guidance and margin pressure. The PharmaMar and Adyen alliances spotlight how Globant embeds AI in high‑value workflows, but they do not immediately change the near term catalyst of turning record pipeline into revenue, or the key risk that slow client spending and early stage AI subscription adoption keep overall growth subdued.
The PharmaMar collaboration is especially relevant here because it showcases Globant Enterprise AI working at scale in a regulated, data intensive domain like oncology R&D. A multi agent system that parses thousands of scientific and regulatory documents with high accuracy reinforces the core catalyst that complex AI integration can deepen client reliance on Globant. At the same time, it highlights an execution risk if clients later internalize similar capabilities or turn to larger rivals offering end to end AI platforms.
Yet beneath these AI wins, investors should also be aware that slower revenue growth and early stage AI model adoption could still...
Read the full narrative on Globant (it's free!)
Globant's narrative projects $3.0 billion revenue and $242.1 million earnings by 2028. This requires 6.1% yearly revenue growth and about a $131.8 million earnings increase from $110.3 million today.
Uncover how Globant's forecasts yield a $73.36 fair value, a 65% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts take a tougher view than the consensus, assuming revenue grows only about 1 percent annually and earnings reach roughly US$199.3 million by 2028, so if you worry that clients might automate more work in house despite wins like PharmaMar, it is worth comparing that more cautious scenario to your own expectations.
Explore 7 other fair value estimates on Globant - why the stock might be worth just $50.00!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Globant research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Globant research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Globant's overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
- The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com